Method and detection reagent for detecting plasma concentration of imatinib mesylate in blood plasma with LC-MS/MS (liquid chromatography-tandem mass spectrometry)

Abstract

The invention discloses a method and a detection reagent for detecting plasma concentration of imatinib mesylate in blood plasma with LC-MS / MS (liquid chromatography-tandem mass spectrometry). The method comprises steps as follows: (i), preparing a standard solution; (ii), preparing an internal standard solution; (iii), pre-processing samples; (iv), drawing a standard curve; (v), measuring the plasma concentration of imatinib mesylate in blood plasma. The detection reagent comprises a moving phase A, a moving phase B, the standard solution and the internal standard solution. The method for detecting the plasma concentration of imatinib mesylate in blood plasma with LC-MS / MS is provided, imatinib and carbamazepine as an internal standard substance can be completely separated with the method, besides, the method is slightly affected by an endogenous substance impurity peak, and recovery rate and precision are high.

Description

technical field [0001] The invention belongs to a method for detecting blood drug concentration of imatinib mesylate, and in particular relates to a method for detecting blood drug concentration of imatinib mesylate in blood plasma by liquid chromatography tandem mass spectrometry and a detection reagent. Background technique [0002] Imatinib mesylate (imatinib) is the first generation of small molecule tyrosine kinase inhibitors. Imatinib mesylate is a small-molecule targeted drug targeting the pathogenesis of chronic myeloid leukemia (CML), and is also recommended as a first-line drug for the treatment of metastatic, recurrent, unresectable, and other gastrointestinal stromal tumors (GIST) and postoperative adjuvant medication, but the efficacy and toxicity of the drug vary greatly among individuals, such as gender, drug metabolism, etc., and are easily affected by other drugs. lifetime. At present, the detection techniques commonly used in clinical testing are mainly b...

AI Technical Summary

Problems solved by technology

At present, the detection techniques commonly used in clinical testing are mainly based on immunoassay methods, but immunoassays have inherent defects in the detection of small molecule compounds

Even with monoclonal antibodies, it is difficult for these antibodies to accurately recognize the single molecular structure of small molecule compounds

In addition, most antibodies are prone to cross-reaction when detecting compounds with similar molecular structures, and the metabolites of imatinib may interfere with the detection and produce false positive detection results

Images